anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tranexamic acid USP tablets is an antifibrinolytic drug administered orally. The chemical name is trans-4-aminomethyl-cyclohexanecarboxylic acid. The structural formula is:

Tranexamic acid is a white crystalline powder. It is freely soluble in water and in glacial acetic acid and is very slightly soluble in ethanol and practically insoluble in ether. The molecular formula is C8H15N02 and the molecular weight is 157.2.

Tranexamic acid USP tablets are provided as white oval-shaped tablets and are not scored. Each tablet is debossed with the marking “FP650.” The active ingredient in each tablet is 650 mg tranexamic acid. The inactive ingredients contained in each tablet are: microcrystalline cellulose, colloidal silicon dioxide, pregelatinized corn starch, povidone, hypromellose, stearic acid, and magnesium stearate.
The present invention relates to a monocyte growth promoting agent, a monocyte growth promoting medium, and a method for producing monocytes. The present invention provides a means for efficiently and easily proliferating monocytes. The present invention provides a monocyte proliferation agent comprising more than one of Flt-3L, IL-3 or IFN-. gamma.for use before differentiation treatment from monocytes to dendritic cells. The present invention also provides a culture medium for proliferating monocytes, which contains at least one of Flt-3L, IL-3 and IFN-. gamma.and is used before the differentiation treatment from monocytes to dendritic cells. The monocyte growth medium of the present invention may contain GM-CSF.
A therapeutic composition for the killing of cancer cells and single celled infectious organisms is new and comprises a bacteriophage, e.g. L or T, or another virus, which has been genetically altered to carry a monoclonal antibody.  A therapeutic composition for the killing of cancer cells and single celled infectious organisms is new and comprises a bacteriophage, e.g. L or T, or another virus, which has been genetically altered to carry a monoclonal antibody. The resulting complex is an aggressive antibody-phage complex (AAPC), which enhances the immune reaction of the organism against the cancer cells or the infectious single celled organisms. The complex comprises a mixture of DNA and transposons (e.g. SINES or LINES) in its head, which, when the antibody interacts with the antigen, it injects into the antigen. There the DNA -transposon mixture mutates the genome of the antigen and thus destroys the cell. An Independent claim is also included for a therapeutical composition comprising a bacteriophage, e.g. L or T, which has been genetically altered to carry an immunoglobulin receptor to form a transporting receptor-phage complex (TRPC). The complex carries a specific DNA or RNA (e.g. a therapeutic gene, reporter gene or antisense DNA or RNA) in its head, which is injected into the ligand, when the ligand and the receptor on the complex interact. The ligand is a target cell and the complex improves gene therapy by specifically targeting and mutating the desired cells.
FIELD: medicine. SUBSTANCE: method involves intravenously administering ozonized 0.09% sodium chloride solution having ozone concentration of 450-500 mcg/l at a dose of 400 ml in all stages of surgical treatment. Ozonized 0.09% sodium chloride solution having ozone concentration of 1000 mcg/l in the amount of 200 ml is introduced via catheter into the urinary bladder for 20 min. The procedure is carried out in known order. The treatment course has 3 intravenous injection every other day, 7 urinary bladder treatments daily during postoperative period. EFFECT: accelerated treatment course; simplified urinary bladder treatment with no antiseptic solutions and special purpose apparatus used.
Subjects will apply Refresh® Dry Eye therapy to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
The invention discloses a formula and a process of magnetic dot film cloth for promoting skin microcirculation and skin care component absorption. The formula of the magnetic dot film cloth for promoting skin microcirculation and skin care component absorption comprises the following components in percentage by mass: 10-50% of ferrite magnetic powder, 2-20% of anion powder, 10-50% of far infrared powder and 20-60% of adhesive; and the magnetic film for promoting skin microcirculation and skin care component absorption adopts the following process: the tencel spunlace fabric is added with ferrite magnetic powder 20%, anion powder 10% and far infrared powder 20% through a plastic dropping process, and high polymer materials are dropped on the fabric and dried at a temperature not higher than 300 ℃ to form a surface film layer. The invention has the beneficial effects that: 1. is beneficial to the blood terminal circulation of human body and promotes the skin nutrition absorption. 2. Effectively prevent moisture from entering the magnetic points, and avoid mutual reaction between the magnetic points. 3. Magnetic powder, negative ion powder and far infrared powder, and can be tested by professional instruments.
The recruited subject subject with periprosthetic joint infection will undergo total four PET scans at two different stages. At first stage, subsequent FDG PET/CT and Ga68 citrate PET/CT scans on different two days will be arranged before infective prosthesis is removed. Eight to twelve weeks after the 1st stage operation, patient will receive two subsequent PET/MR scans using Ga-68 Citrate and FDG on different two days, respectively. The PET images will be visually examined by a nuclear medicine physician and will be reported if any abnormal uptake higher than background by their location and standard uptake value (SUV). The CT/MR images will be reported by a radiologist using standard reading procedures, respectively. The lesions on the PET scan will be correlated to the computed tomography and magnetic resonance images, and the final sensitivity, specificity, and accuracy will be calculated according to the histopathology results or composite clinical and laboratory data.

On the scan day using Ga68-Citrate, baseline electrocardiogram, complete blood count (CBC), and biochemistry profiles including serum alanine transaminase (ALT) and creatinine (Cre) level will be done prior to injection of the radio-pharmaceutical (Ga68-Citrate). Vital signs will be measured before the scan beginning. After completing exam, the electrocardiogram and vital signs will be measure again, and the subject will be released if there is no discomfort. The subject will return to the clinic within 1 week after Ga68-citrate scan. CBC, biochemistry profiles will be checked again for safety monitoring.
Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Sorafenib 400mg twice daily (Bid) oral dosing.
The Korean traditional medicine, Kyoung-ok-ko with improved pharmacological activity and a process for preparing the same medicine are provided to improve anti-oxidizing activity and anti-cancer activity compared to the prior Kyoung-ok-ko, so that it is useful for metabolism enhancement, improvement of weak constitution and cancer prevention. The process for preparing the Korean traditional medicine, Kyoung-ok-ko with improved pharmacological activity comprises the steps of: (i) mixing 40-60%(w/w) of steamed Rehmanniae Radix paste, 4-8%(w/w) of ginseng powder, 5-15%(w/w) of Poria cocos WOLF. Powder and 30-40%(w/w) of honey; and (ii) inserting and sealing the mixture into a vessel, heating the vessel in a double boiler at 90-110 deg. C for 60-80 hours, cooling the mixture at room temperature, heating the vessel in a double boiler at 90-110 deg. C for 12-36 hours, and cooling the mixture at room temperature, wherein the steamed Rehmanniae Radix paste is prepared by steaming Rehmanniae Radix at 90-110 deg. C and 5-15 atmospheric pressure for 10-30 minutes, and subjecting the steamed Rehmanniae Radix to Jet mill or colloid mill.
A fragrance composition having an excellent diffusivity and long-lasting property of fragrance and a cosmetic, toiletry, bath composition, food and drink and pharmaceutical having an excellent diffusivity and long-lasting property of fragrance by using a novel fixative. A compound represented by the following general formula (1) is incorporated in a fragrance composition or the foregoing products. The amount of the compound of the general formula (1) to be incorporated in the fragrance composition is preferably from 0.01 to 90% by weight. The amount of the compound of the general formula (1) to be incorporated directly in the foregoing products is preferably from 0.0001 to 2.0 times (by weight) the weight of the aroma composition and/or composition to be incorporated therein. In this arrangement, a fragrance composition or products having an enhanced diffusivity and long-lasting property of fragrance can be obtained without causing any safety problem on human being. Wherein A represents H or OH group; B represents H or methyl group; and n represents an integer of from 0 to 2.
This is a single site, parallel, non-blinded, randomized controlled trial to assess the safety and efficacy of 12 weeks of structured IY vs. enhanced usual care in adults with high-normal to stage I HTN. All potential subjects will be screened first by telephone and then by an outpatient visit at the General Clinical Research Center (GCRC) at either the hospital of the University of Pennsylvania (HUP) or the Presbyterian Medical Center (PMC). Eligible subjects will then make 4 visits to the GCRC where, during 3 visits, they will be admitted overnight to have non-invasive 24 hour recordings of blood pressure and heart rate variability as well as periodic blood and urine collections. In order to assess durability of biologic effects once the formal intervention is stopped, we added a 4 week follow up visit. The entire study duration is 18 weeks (16 weeks post-randomization) and includes a total of 5 visits. Subjects will be randomized to either the IYP or Blood Pressure Education Program (BPEP) which will be incorporated into off-site, small group classes.
Three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure/infusion using a microdialysis device. All subjects will receive Sodium Chloride solution perfused for 30 minutes followed by Retapamulin perfusion for 90 minutes and then Saline perfusion will occur during the washout period.
Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
PURPOSE: To provided the blocker that consists of a crosslinked polymer supported on a matrix which has branched chains each provided with a hydrogen bonding part and an ionic bonding part and in which the polymer branched chains are linked together, and is effective in lowering the serum cholesterol level by administering a small dose of the blocker. CONSTITUTION: This blcoker has improved bile acid blocking ability and by administering a small dose of the blocker, uncomfortable side effects can be reduced to the minimum. The blocker consists of a crosslinked polymerization product that is produced from a mixture of a first monomer represented by the formula I and a second monomer represented by the formula II. In the formula I: R1 is H or an alkyl group; R2 is -N(R7 )R8 , or the like, wherein each of R7 and R8 is H or an alkyl group; R3 is H or an alkyl group; and (a) is an integer of 1 to 20. In the formula II: E is O, or the like; R10 is H or an alkyl group; and D is -(CHR11 )g wherein R11 is H or an alkyl group and (g) is an integer of 1 to 20.  Especially, a polymerization product produced from a mixture of about 95.6 mol.% of dimethylaminopropylmetacrylamide and about 4.4 mol.% of N,N'-hexamethylenebis(methacrylamide) is preferred. Further, optionally, the blocker contains a cholesterol biosynthesis inhibitor such as HMG-CoA reductase inhibitor.
As the global population ages at an unprecedented rate, the prevalence of age-related diseases is increasing, making inflammaging - a phenomenon characterized by a chronic, low-grade inflammatory state that follows aging - a significant concern. Understanding the mechanisms of inflammaging and its impact on health is critical for developing strategies to improve the quality of life and manage health in the aging population. Despite their crucial roles in various biological processes, including immune response modulation, N-glycans, oligosaccharides covalently attached to many proteins, are often overlooked in clinical and research studies. This repeated oversight is largely due to their inherent complexity and the complexity of the analysis methods. High-throughput N-glycan analysis has emerged as a transformative tool in N-glycosylation research, enabling cost- and time-effective, detailed, and large-scale examination of N-glycan profiles. This paper is the first to explore the application of high-throughput N-glycomics techniques to investigate the complex interplay between N-glycosylation and the immune system in aging. Technological advancements have significantly improved Nglycan detection and characterization, providing insights into age-related changes in Nglycosylation. Key findings highlight consistent shifts in immunoglobulin G (IgG) and plasma/serum glycoprotein glycosylation with age, with a pronounced rise in agalactosylated structures bound to IgG that also affect the composition of the total plasma N-glycome. These N-glycan modifications seem to be strongly associated with inflammaging and have been identified as valuable biomarkers for biological age, predictors of disease risk, and proxy biomarkers for monitoring intervention efficacy at the individual level. Despite current challenges related to data complexity and methodological limitations, ongoing technological innovations and interdisciplinary research are expected tofurther advance our knowledge of glycan biology, improve diagnostic and therapeutic strategies, and promote healthier aging. The integration of glycomics with other omics approaches holds promise for a more comprehensive understanding of the aging immune system, paving the way for personalized medicine and targeted interventions to mitigate inflammaging. In conclusion, this paper underscores the transformative impact of high-throughput Nglycan analysis in aging and inflammaging.
After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
A procedure for preparing compounds of cefem. Is to make reaction a composite formula general (I) with formoaldehido. A composite of general formula (II) is obtained that optionally can be subject to different transformations. R1 is a substituted amino-heterociclic group that may contain halogen, a protected-heterociclic amino group substituted. R1 is carboxi or a protected carboxi group; a lower alcoholene that may contain a selected substitute of the groups constituted by amino, an amino-protected group, hidroxi, oxo and the group = n or elevated 4. * formula *. (Machine-translation by Google Translate, not legally binding)
PURPOSE: An external use skin composition containing a phytomucin extract is provided to enhance skin elasticity and moisturization. CONSTITUTION: An external use skin composition contains 0.0001-20wt% of phytomucin extract as an active ingredient. The phytomucin extract is a Discorea bulbifera extract, an Opuntia littoralis extract, a Codonopsis lanceolata extract, a Discorea japonica Thunb. extract, a Nelumbo nucifera Gaertn extract, or a mixture thereof. The composition is used for skin moisturization and anti-aging, and for enhancing skin elasticity. [Reference numerals] (AA) DPPH radical scavenging activity; (BB) Concentration(PPM); (CC) Discorea bulbifera extract; (DD) Opuntia littoralis extract; (EE) Codonopsis lanceolata extract; (FF) Discorea japonica Thunb. extract; (GG) Nelumbo nucifera Gaertn extract; (HH) Opuntia littoralis and Codonopsis lanceolata extract; (II) Discorea japonica Thunb. and Nelumbo nucifera Gaertn extract
In china, the prevalence of food allergy in in preschool children was about 7%. Diagnosis of food allergy is mainly based on a combination of clinical history, clinical manifestations and related supplementary examinations, including skin prick testing (SPT), serum specific IgE testing (sIgE), and oral food challenge (OFC). Although OFC is the gold standard for allergy diagnosis, it is rarely conducted in clinic for the low safety. Until now, serum specific IgE assays against allergen are the most commonly used in vitro diagnostic approach in China. However, specific-IgEs are sensitive, but not specific for diagnosis of food allergy. Moreover, food allergy could not be excluded when sIgE results are negative (\<0.35KU/L). Thus, more accurate and safer test is needed. BAT was shown to have good accuracy for food allergy diagnosis. BAT is an ex vivo functional assay that measures by flow cytometry the degree of basophil activation after stimulation with an allergen. However, experimental strategies for BAT reported in the literatures are different. Some research even used 12 kinds of antibodies to identity basophils. In previous study, the investigators established BAT using 4 kinds of antibodies. Basophils could be distinguished well from other cells. In this study, children aged 4 months to 6 years who visit pediatric and emergency department, and are suspected with egg allergy will be included in study. Detailed information about clinical history and manifestations will be collected. Serum sIgE to food and BAT will be detected. The proposed study intends to analyze sensitivity and specificity of the established BAT according to the clinical comprehensive diagnosis results, and evaluate its efficacy to diagnose food allergy in children.
Patients undergo strength training sessions twice weekly supervised by a licensed and specialized personal trainer via the internet (e.g., remote access) for 6 months. Patients also wear a FitBit device and receive prompts via email or text on a cell phone or other electronic device to incrementally increase physical activity over 6 months.
BACKGROUND: Due to medical and surgical advancements, the population of adult patients with congenital heart disease (ACHD) is growing. Despite successful therapy, ACHD patients face structural sequalae, placing them at increased risk for heart failure and arrhythmias. Left and right ventricular function are important predictors for adverse clinical outcomes. In acquired heart disease it has been shown that echocardiographic deformation imaging is of superior prognostic value as compared to conventional parameters as ejection fraction. However, in adult congenital heart disease, the clinical significance of deformation imaging has not been systematically assessed and remains unclear.
METHODS: According to the Preferred Reporting Items for Systematic Reviews checklist, this systematic review included studies that reported on the prognostic value of echocardiographic left and/or right ventricular strain by 2-dimensional speckle tracking for hard clinical end-points (death, heart failure hospitalization, arrhythmias) in the most frequent forms of adult congenital heart disease.
RESULTS: In total, 19 contemporary studies were included. Current data shows that left ventricular and right ventricular global longitudinal strain (GLS) predict heart failure, transplantation, ventricular arrhythmias and mortality in patients with Ebstein's disease and tetralogy of Fallot, and that GLS of the systemic right ventricle predicts heart failure and mortality in patients post atrial switch operation or with a congenitally corrected transposition of the great arteries.
CONCLUSIONS: Deformation imaging can potentially impact the clinical decision making in ACHD patients. Further studies are needed to establish disease-specific reference strain values and ranges of impaired strain that would indicate the need for medical or structural intervention.
PURPOSE:A drug for inhibiting melanization, containing a placental extract and KOJIC acid or a derivative thereof and used for external therapy of pigmentation, e.g. chloasma, etc. CONSTITUTION:A drug for external use, obtained by containing an aqueous solution prepared by passing a placental of an animal, e.g. human, cattle, etc., through means, e.g. washing, crushing, freezing, etc., extracting a water-soluble substance with water and removing impurities or placental extract essence, particularly preferably human-derived placental extract, and KOJIC acid or a derivative thereof, preferably at 10:3-0.1 ratio by pts.wt. and used for inhibiting melanization. The drug is extremely effective for preventing and treating pigmentation by synergistic effect of the KOJIC acid and placental extract by applying the drug for external use to affected parts.
LOCAL PROBLEM: Sternal wound infections (SWIs), whether superficial or deep, are associated with increased morbidity, mortality, and costs. From 2016 to 2017, our facility saw a 50% decrease in SWIs among patients undergoing cardiothoracic surgery with sternotomy. From 2017 to 2018, however, we identified a 33% increase in SWIs, prompting us to address our cardiac nurses' sternal wound care education and practice.
PURPOSE: The purpose of our quality improvement (QI) project was to identify opportunities for improvement in postoperative sternal incision care and to implement evidence-based processes to reduce the incidence of SWIs among cardiothoracic surgery patients.
METHODS: A literature review was performed to identify interventions focused on evidence-based SWI reduction. During the first quarter of 2019, our postoperative incision care guidelines were revised and released to staff, a new surgical wound cleansing product was supplied, and RN education was provided. Cardiac nurses were surveyed in April 2019 to identify any remaining knowledge and practice deficits and to assess their adherence to the new guidelines. The survey responses helped us to further improve our nurse education. We also provided periodic nurse reeducation and enhanced patient and family education. All such interventions were implemented by the end of June 2019.
RESULTS: Between January and June 2019, we had one SWI. From July 2019 through December 2020, an 18-month period, we experienced zero SWIs. Although beginning in 2021, we saw an increase in SWIs-four in 2021 and five in 2022-our incidence rates remain below 0.5% and we continue to work toward an SWI goal of zero.
CONCLUSION: This QI project identified opportunities for improvement, implemented evidence-based strategies for wound care and education, and successfully achieved a zero SWI rate for a period of 18 months.